Advanced therapy manufacturers in the UK have come together to raise awareness of the potential of next generation therapies and to support their development.
The Cell & Gene Collective has been launched with the participation and support of Astellas Pharma (TYO: 4503), bluebird bio (Nasdaq: BLUE), Bristol Myers Squibb (NYSE: BMY), Novartis (NOVN: VX) and Kite, a division of Gilead Sciences (Nasdaq: GILD).
In a statement, the group said that the UK has been “a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze